HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elisabeth von Guggenberg Selected Research

Cholecystokinin B Receptor

6/2021Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.
1/2021A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer.
1/2021Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma.
12/2020Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements via the Inclusion of Proline into the Peptide Sequence.
1/2019DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
12/2018A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.
1/2018Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Elisabeth von Guggenberg Research Topics

Disease

18Neoplasms (Cancer)
06/2021 - 11/2006
10Prostatic Neoplasms (Prostate Cancer)
11/2021 - 11/2008
9Thyroid Neoplasms (Thyroid Cancer)
01/2021 - 03/2004
3Neoplasm Metastasis (Metastasis)
01/2020 - 06/2017
2Carcinoma (Carcinomatosis)
06/2021 - 11/2008
1medullary Thyroid cancer
11/2021
1Primitive Neuroectodermal Tumors (PNET)
10/2016
1Lung Neoplasms (Lung Cancer)
08/2011
1Infertility (Sterility)
11/2007
1Melanoma (Melanoma, Malignant)
11/2006

Drug/Important Bio-Agent (IBA)

10Peptides (Polypeptides)IBA
01/2021 - 01/2012
7Cholecystokinin B ReceptorIBA
06/2021 - 01/2018
5gallium 68 PSMA-11IBA
11/2021 - 05/2017
5minigastrinIBA
06/2021 - 06/2012
3Furosemide (Lasix)FDA LinkGeneric
11/2021 - 01/2021
31,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
01/2021 - 06/2012
3LigandsIBA
01/2019 - 12/2015
3AntigensIBA
09/2017 - 05/2017
3Liposomes (Liposome)IBA
01/2013 - 01/2012
2RadiopharmaceuticalsIBA
11/2021 - 08/2016
2Prostate-Specific Antigen (Semenogelase)IBA
11/2021 - 06/2017
2Indium-111IBA
12/2020 - 01/2012
2PSMA-11IBA
09/2017 - 05/2017
2Cholecystokinin (Pancreozymin)IBA
08/2016 - 08/2011
2Somatostatin Receptors (Somatostatin Receptor)IBA
12/2015 - 03/2004
2IntegrinsIBA
01/2012 - 11/2006
1N,N'- bis(2- hydroxy- 5- (ethylene- beta- carboxy)benzyl)ethylenediamine N,N'-diacetic acidIBA
11/2021
1Sodium ChlorideFDA LinkGeneric
11/2021
1Lutetium-177IBA
12/2020
1177Lu-PSMA-617IBA
01/2020
1Radioisotopes (Radionuclides)IBA
10/2018
1Sodium Fluoride (Ossin)FDA Link
10/2018
1Amino AcidsFDA Link
01/2018
1Gallium-68IBA
01/2017
1GastrinsIBA
08/2016
1Octreotide (Sandostatin)FDA LinkGeneric
12/2015
1lanreotide (Somatuline)FDA Link
12/2015
1Glucose (Dextrose)FDA LinkGeneric
12/2015
1Cholecystokinin Receptors (Cholecystokinin Receptor)IBA
06/2012
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2012
1MicellesIBA
01/2012
1Antisense OligonucleotidesIBA
12/2010
1OligonucleotidesIBA
12/2010
1insulin receptor-related receptor (IRR)IBA
11/2008
1Proteins (Proteins, Gene)FDA Link
11/2008
1EndotoxinsIBA
11/2007
1EDDA (NiEDDA)IBA
03/2004

Therapy/Procedure

6Therapeutics
11/2021 - 01/2017
3Radiotherapy
01/2019 - 11/2008
2Castration
03/2020 - 01/2020
1Precision Medicine
01/2021
1Gamma Cameras (Gamma Camera)
11/2006